Abstract
BackgroundBreast cancer is one of the most prevalent forms of cancer in women. Breast-specific gamma imaging (BSGI) is a diagnostic imaging method that uses sestamibi-labelled 99Tc and a dedicated gamma camera to localize malignant lesions in breast tissue. The aim of this study is to investigate if the current acquisition protocol for BSGI at our hospital is optimized for the detection of lesions in our patients.MethodsWe analyzed patient data and performed a phantom study with a Dilon 6800 gamma camera. The patient data were collected from a group of 13 patients (740 MBq 99mTc-sestamibi, four views per patient were dynamically acquired with a frame duration of 30 s per frame and a total acquisition time of 8 min per view). Reduced-time static images were created, and contrast-to-noise ratios of identified hotspots were determined for different acquisition times. For the phantom study, we used a contrast detail phantom to investigate the contrast and resolution properties, within the range of relevant clinical acquisition parameters. The phantom was filled with a concentration of 80 MBq in 500 ml of water, and we dynamically acquired frames for a total acquisition time of 60 min using a general purpose (GP) collimator. To compare the GP collimator with the high-resolution collimator, a second acquisition was made for both collimators with a total acquisition time of 16 min.ResultsThe initial analysis of BSGI scans of the 13 patients showed that a dose reduction by a factor of 3 would not have reduced the number of observable hotspots in each of the acquired views. However, a subsequent systematic analysis of our protocol with a contrast-detail phantom showed that dose reduction results in a lower observability of hotspots, whereas increased doses resulted in a higher observability.ConclusionWe believe that the results of our phantom study are relevant for clinical practice and that further dose reduction cannot be recommended for the BSGI exams at our hospital and that an increase of the administered activity should be considered.
Highlights
Breast cancer is one of the most prevalent forms of cancer in women
In this study, we presented a contrast-to-noise ratio (CNR) analysis of the Breast-specific gamma imaging (BSGI) acquisition protocol at our hospital
Patients who are referred for a BSGI examination at our hospital already underwent mammography, ultrasound and magnetic resonance imaging (MRI) exams, and there is often a strong suspicion for malignant disease; additional information about the size or focality of the disease are required
Summary
Breast cancer is one of the most prevalent forms of cancer in women. Breast-specific gamma imaging (BSGI) is a diagnostic imaging method that uses sestamibi-labelled 99Tc and a dedicated gamma camera to localize malignant lesions in breast tissue. The mammogram is not conclusive in all cases, especially in women with dense breast tissue; mammograms can be difficult to interpret and can lead to ambiguous findings. As a result, these patients are referred for a magnetic resonance imaging (MRI) scan. We have a single-head breast-specific gamma camera (Dilon 6800, Dilon Technologies Inc., Newport News, VA, USA) for which we want to explore the possibilities of reducing acquisition times or, equivalently, further reducing patient dose. This study concentrates on dose optimisation of the BSGI protocol at our hospital, and we introduce a contrast-to-noise ratio (CNR) analysis methodology and a phantom-based approach to determine if imaging longer (or equivalently giving a higher dose) could lead to the observation of more hotspots. We applied the CNR analysis to data from a small group of patients
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
